Abstract | BACKGROUND: METHODS: A systematic literature search of the PubMed, EMBASE, and Web of Science databases was performed to identify relevant studies and trials. Statistical analysis was conducted using STATA 11.2 software. RESULTS: Nine cohort studies were included, corresponding to a total of 43,115 PsA patients undergoing therapy. A significant positive association between therapy and increased risk for overall malignancy was found relative to the general population as the reference group (pooled RR, 1.29; 95% CI: 1.04-1.60). High heterogeneity was found (I2 = 71.37%). Subgroup analysis reported that PsA patients treated with conventional synthetic disease modifying antirheumatic drugs (csDMARDs) presented increased cancer risk (pooled RR, 1.75; 95% CI: 1.40-2.18) but patients treated with biological disease modifying antirheumatic drugs (bDMARDs) did not (pooled RR, 0.957; 95% CI: 0.80-1.14). Compared to controls, patients with PsA undergoing treatment specifically are at increased risk for non- melanoma skin cancers (pooled RR, 2.46; 95% CI: 1.84-3.28). CONCLUSIONS: This study allowed the estimation of cancer risk in PsA patients during therapy. Large-scale longitudinal studies will be essential to draw firm conclusions regarding PsA-associated risk for treatment-induced malignancy.
|
Authors | Xuan Luo, Chuiwen Deng, Yunyun Fei, Wen Zhang, Yongzhe Li, Xuan Zhang, Yan Zhao, Xiaofeng Zeng, Fengchun Zhang |
Journal | Seminars in arthritis and rheumatism
(Semin Arthritis Rheum)
Vol. 48
Issue 4
Pg. 626-631
(02 2019)
ISSN: 1532-866X [Electronic] United States |
PMID | 29929736
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)
|
Copyright | Copyright © 2018 Elsevier Inc. All rights reserved. |
Chemical References |
- Antirheumatic Agents
- Biological Products
|
Topics |
- Antirheumatic Agents
(adverse effects)
- Arthritis, Psoriatic
(drug therapy)
- Biological Products
(adverse effects)
- Humans
- Incidence
- Neoplasms
(epidemiology, etiology)
- Risk
|